Vaxart (OTCMKTS:VXRT) Share Price Passes Below 200 Day Moving Average - Here's Why

Key Points

• Vaxart shares fell below their 200-day moving average of $0.62, trading as low as $0.4901 before last changing hands at $0.5025.
• Zacks Research upgraded the stock to “Hold,” matching the broader analyst consensus, which currently rates Vaxart a “Hold.”
• Vaxart exceeded quarterly expectations, reporting a loss of $0.06 per share versus the projected $0.12 loss and revenue of $27.18 million versus the $26.21 million estimate; institutional investors own 18.05% of the company.

Vaxart, Inc. (OTCMKTS:VXRT - Get Free Report) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.62 and traded as low as $0.4901. Vaxart shares last traded at $0.5025, with a volume of 238,924 shares trading hands.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Vaxart to a "hold" rating in a research report on Thursday, July 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Vaxart currently has an average rating of "Hold".

Vaxart Stock Performance

The business's 50 day moving average is $0.54 and its two-hundred day moving average is $0.62. The firm has a market capitalization of $122.20 million, a PE ratio of 3.14 and a beta of 1.10.

Vaxart (OTCMKTS:VXRT - Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.06. The firm had revenue of $27.18 million for the quarter, compared to the consensus estimate of $26.21 million. Vaxart had a return on equity of 53.04% and a net margin of 15.88%. As a group, equities research analysts predict that Vaxart, Inc. will post -0.68 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in VXRT. Raymond James Financial Inc. grew its holdings in Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company's stock valued at $107,000 after buying an additional 34,075 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Vaxart in the second quarter worth about $794,000. Creative Planning purchased a new stake in shares of Vaxart in the second quarter worth about $33,000. Goldman Sachs Group Inc. bought a new position in shares of Vaxart in the first quarter valued at approximately $31,000. Finally, Jones Financial Companies Lllp boosted its position in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock valued at $196,000 after acquiring an additional 478,111 shares during the period. Institutional investors own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source